Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 9/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2960694 | 0.88 | BACE1 (0.32) | PGRBACE1IDO1METAP2ALDH1A1 | |
| SCHEMBL2960691 | 0.88 | BACE1 (0.32) | PGRBACE1IDO1METAP2ALDH1A1 | |
| SCHEMBL4549187 | 0.87 | BACE1 (0.39) | BACE1 | |
| SCHEMBL7541964 | 0.82 | BACE1 (0.43) | PGRBACE1MAPTPARP10PARP11 | |
| SCHEMBL4556676 | 0.82 | PGR (0.36) | PGRXDHBACE1IDO1METAP2 | |
| SCHEMBL4559956 | 0.81 | ATP4A (0.38) | PGRXDHBACE1NPC1ALDH1A1 | |
| SCHEMBL8437235 | 0.81 | ADORA3 (0.34) | PGRBACE1ALDH1A1MAPTMAPK14 | |
| SCHEMBL8437193 | 0.80 | CYP2A6 (0.36) | PGRXDHBACE1MAPK14PARP10 | |
| SCHEMBL4559993 | 0.80 | PGR (0.40) | PGRBACE1MAPTPARP10PARP11 | |
| SCHEMBL8414505 | 0.79 | XDH (0.35) | PGRXDHBACE1IDO1METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| US-8168641-B2 | Aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-01 | — | — | US | disclosed |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232064-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | PGR 2393/4885XDH 349/4885BACE1 3/4885 |
| US-20070287692-A1 | ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, BACE1 | PGR 2393/4885XDH 349/4885BACE1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.